Nanjing Leads Biolabs Co., Ltd. has announced the successful completion of the safety run-in stage of a Phase II clinical trial for its bispecific antibody, Opamtistomig (LBL-024), targeting advanced biliary tract cancer (BTC). The trial, led by Dr. Jian Zhou from Zhongshan Hospital, Fudan University, has transitioned into the expansion phase following favorable safety results and promising preliminary efficacy data. The safety run-in cohort included 20 patients, all of whom tolerated the combination of Opamtistomig with chemotherapy well, showing no new safety signals and demonstrating trends in tumor reduction.

The significance of these findings lies in Opamtistomig’s dual mechanism of action, which simultaneously blocks PD-L1 to reverse immune suppression and activates the 4-1BB co-stimulatory pathway to enhance T-cell responses. This approach aims to improve anti-tumor activity, particularly in challenging cases of immunotherapy-resistant tumors. Current first-line treatments for advanced BTC, primarily PD-1/L1 inhibitors combined with chemotherapy, have shown limited efficacy, with median overall survival improvements being modest and low objective response rates. Opamtistomig’s potential to address these gaps could represent a substantial advancement in treatment options for this aggressive cancer type.

The advancement of Opamtistomig into the expansion phase underscores its potential to reshape therapeutic strategies in oncology, particularly for cancers with high unmet medical needs. As Leads Biolabs accelerates patient enrollment and plans for a confirmatory study, this bispecific antibody could pave the way for more effective immunotherapies, potentially shortening drug development timelines and enhancing patient outcomes in advanced biliary tract cancer and beyond. The ongoing exploration of Opamtistomig across various malignancies further emphasizes its broad-spectrum applicability in the immuno-oncology landscape.

Source: globenewswire.com